Skip to main content
. 2022 Jan 16;13(2):2296–2307. doi: 10.1080/21655979.2021.2024389

Figure 5.

Figure 5.

miR-665 counteracts the malignant properties of ADORA2A-AS in CML cells. (a, b) The expression of miR-665 in K562 and KCL22 cells transfected with miR-665 mimics or mimic control. K562 and KCL22 cells were co-transfected with miR-665 mimic and pcDNA3.1-ADORA2A-AS or alone, and subjected to (c, d) CCK8 assay for cell proliferation, (e) flow cytometry for cell apoptosis analysis, and (f) flow cytometry for cell cycle analysis. *P < 0.05, **P < 0.01, ***P < 0.001;. #P < 0.05, ##P < 0.01.